Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, 2-Arm, Open-Label, Ph-II Study of Abemaciclib Combined With ET w/ or w/o CT With Paclitaxel as 1L in Patients With Unresectable Locally Advanced or Metastatic HR(+)/HER2(-) BC With Aggressive Disease Criteria

NCT04603183 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT04603183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04603183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, 2-Arm, Open-Label, Ph-II Study of Abemaciclib Combined With ET w/ or w/o CT With Paclitaxel as 1L in Patients With Unresectable Locally Advanced or Metastatic HR(+)/HER2(-) BC With Aggressive Disease Criteria
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Completed
Start date
June 2, 2021
Completion date
June 30, 2025
Enrollment
162 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic